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Abstract 
Objective: The occurrence of non‑alcoholic fatty liver disease (NAFLD) is globally increasing. To challenge the current 
incidence of NAFLD, non‑invasive markers that could identify patients at risk or monitor disease progression are an 
important need. Copper intake and organ copper concentrations have earlier been linked to NAFLD progression, but 
serum copper does not adequately represent the disease state. Cu atoms occur under the form of two stable iso‑
topes, 63Cu and 65Cu, and the ratio of both (expressed as δ65Cu, in  ‰) in blood serum has been shown to be altered 
in chronic liver disease. To assess whether the Cu isotope ratio might predict disease occurrence and progression of 
NAFLD, the serum Cu isotopic composition of patients with different stages of NAFLD was determined.
Results: Our results showed that serum δ65Cu values were lower in NAFLD patients, already at the level of simple 
steatosis, and remained stable during further disease progression. ROC analysis shows an almost perfect diagnostic 
ability of serum δ65Cu values for NAFLD, but no discrimination between different severity degrees could be made. 
Therefore, the serum Cu isotopic composition might show potential for early diagnosis of NAFLD patients.
Keywords: Liver steatosis, Non‑alcoholic steatohepatitis, Cu isotopes, Multi collector inductively coupled 
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is the most 
common liver disease with a global current prevalence 
of 24% [1]. In the past two decades, its incidence has 
increased about fivefold, especially in young adults [2]. 
NAFLD can range from simple hepatic steatosis (fat 
accumulation, non-alcoholic fatty liver, NAFL) to liver 
inflammation (non-alcoholic steatohepatitis, NASH), 
which can evolve to liver fibrosis with varying degree of 
liver dysfunction [3]. Since patients with steatohepatitis 
are at increased risk of fibrosis development and might 
even develop hepatocellular carcinoma (HCC), and no 
pharmacological option for any stage of NAFLD is avail-
able so far, it is of interest to detect patients early in dis-
ease progression.
Recently, there has been a growing interest in high-pre-
cision Cu isotopic analysis, i.e. evaluating the 65Cu/63Cu 
ratio (expressed as δ65Cu, in   ‰), as a diagnostic and 
prognostic tool for liver disease [4–7]. 63Cu and 65Cu are 
the two stable Cu isotopes that occur naturally, showing 
Open Access
BMC Research Notes
*Correspondence:  marta.costasrodriguez@UGent.be; lindsey.
devisscher@UGent.be
†Sanne Van Campenhout and Agustina A. M. B. Hastuti contributed 
equally to this work
†Marta Costas‑Rodríguez and Lindsey Devisscher contributed equally to 
this work
2 Department of Basic and Applied Medical Sciences–Gut Liver 
Immunopharmacology Unit, Ghent University, Corneel Heymanslaan 10 
entrance 36–floor 3, 9000 Ghent, Belgium
3 Department of Chemistry, Atomic and Mass Spectrometry–A&MS 
Research Unit, Ghent University, Campus Sterre, Krijgslaan 281‑S12, 
9000 Ghent, Belgium
Full list of author information is available at the end of the article
Page 2 of 6Van Campenhout et al. BMC Res Notes          (2020) 13:225 
small, but systematic variations in their abundance ratio 
under certain disease conditions that can be reliably 
quantified [8–10]. It has been published recently that 
patients destined for bariatric surgery may show lower 
serum δ65Cu values [11]. Bariatric surgery is performed 
on morbidly obese patients to reduce food intake and 
obtain weight loss, and NAFLD is a prominent health 
risk in these patients. In the latter study, no liver biopsies 
were taken and no fibroscan was used to assess NAFLD 
in this patient cohort, and thus the initial status of liver 
disease was not known.
Therefore, we have investigated the diagnostic potential 
of serum δ65Cu values for different stages of NAFLD. We 
have collected serum from patients with biopsy-proven 
NAFLD with varying severity, and subjected these sam-
ples to high-precision Cu isotopic analysis via multi-
collector inductively coupled plasma-mass spectrometry 
(MC-ICP-MS).
Main text
Materials and methods
Patient cohort
A patient cohort of 10 NAFL and 14 NASH patients was 
recruited at the Ghent University Hospital within the 
context of a previous study (Table  1 for patient charac-
teristics). Non-cirrhotic patients were scheduled for 
bariatric surgery. Specific clinical, biochemical, histo-
logical and/or radiographic criteria were used to exclude 
liver disease of other aetiologies, including cholestatic, 
alcohol-induced or drug-induced liver disease and viral 
or auto-immune hepatitis. All patients had biopsy-con-
firmed NAFLD and a negative history of alcohol abuse 
(average daily consumption of less than 20  g EtOH). 
Healthy controls from previous studies were used for 
comparison (Table 1) [11–13].
Table 1 Clinical characteristics of the patient cohort. Results are expressed as mean ± 95% CI
NAFL non-alcoholic fatty liver, NASH non-alcoholic steatohepatitis, BMI body mass index, AST aspartate aminotransferase, ALT alanine aminotransferase, GGT 
γ-glutamyltransferase, Hb Haemoglobin, HbA1c haemoglobin A1c, LDL low-density lipoprotein, HDL high-density lipoprotein, HOMA-IR Homeostasis Model 
Assessment Insulin Resistance
Characteristic NAFL (n = 10) NASH F0-F2 (n = 10) NASH F4 (n = 4)
Age (years) 39.8 ± 7.8 47.5 ± 8.9 66.8 ± 17.1
Gender (M %/F %) 10/90 0/100 100/0
BMI (kg m−2) 41.6 ± 6.5 42.7 ± 7.2 29.0 ± 11.2
Type 2 diabetes (%) 10 30 100
AST (U l−1) 23.3 ± 4.2 32.6 ± 17.0 31.8 ± 21.5
ALT (U l−1) 24.2 ± 5.4 39.4 ± 24.3 33.3 ± 11.7
GGT (U l−1) 16.0 ± 4.2 51.5 ± 27.8 139.5 ± 142.6
Platelets  (103 µl−1) 274.5 ± 29.9 297.3 ± 64.1 133.8 ± 87.0
Hb (g dl−1) 13.2 ± 0.6 13.5 ± 1.3 12.4 ± 3.4
HbA1c (%) 5.6 ± 0.3 6.1 ± 1.2 6.2 ± 1.8
Total cholesterol (mg dl−1) 186.8 ± 21.1 195.4 ± 40.0
LDL (mg dl−1) 94.2 ± 16.3 103.2 ± 21.0
HDL (mg dl−1) 66.3 ± 11.8 44.4 ± 13.0
Triglycerides (mg dl−1) 121.7 ± 26.7 219.9 ± 76.5
Bilirubin (mg dl−1) 0.4 ± 0.1 0.4 ± 0.1
Fasting glucose (mg dl−1) 98.2 ± 18.5 97.5 ± 9.6
HOMA‑IR 4.4 ± 2.4 6.9 ± 2.9
Iron (µg dl−1) 76.6 ± 26.4 66.3 ± 19.0
Transferrin (mg dl−1) 2.9 ± 0.3 2.6 ± 0.7
Ferritin (µg l−1) 60.0 ± 38.6 155.1 ± 122.3
Copper (µg dl−1) 137.4 ± 38.4 117.3 ± 39.6
Control population
REF Age, years Gender (M%/F%) n
[11] 43.8 ± 8.5 0/100 10
[12] 23–48 100/0 5
[13] 51.57 ± 6.9 100/0 7
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Clinical evaluation
Anthropometric measurements of all patients were taken 
and the body mass index (BMI) was calculated as body 
weight/height2 (kg  m−2). Blood samples from patients 
were collected, centrifuged (10  min, 4  °C, 350  g), and 
serum was stored at − 80 °C until analysis. Thawed serum 
was analysed for the levels of aspartate aminotransferase 
(AST), alanine aminotransferase (ALT), γ-glutamyl trans-
peptidase (GGT), bilirubin, haemoglobin, triglycerides, 
high-density lipoprotein (HDL) cholesterol, low-density 
lipoprotein (LDL) cholesterol, total serum cholesterol, 
fasting glucose, haemoglobin A1c (HbA1c) and insulin 
and complete blood count. Insulin resistance was esti-
mated by the homeostasis model assessment-insulin 
resistance (HOMA-IR) [14], and the presence of diabetes 
mellitus (according to the American Diabetes Associa-
tion criteria [15]) was evaluated. In addition, iron, trans-
ferrin, ferritin and copper serum levels were determined.
Formalin-fixed liver biopsies were routinely processed 
and stained with haematoxylin and eosin, and Masson’s 
trichrome. All biopsies were blinded and evaluated by an 
experienced pathologist according to the NASH clinical 
research network scoring system [16].
Serum isotopic analysis
Serum samples (400 µL), were thawed and digested 
in perfluoroalkoxy (PFA) digestion vessels (Savillex, 
USA) with a 2:1 v/v mixture of 14 M pro analysis  HNO3 
(Chem-lab, Belgium and additionally purified by means 
of sub-boiling distillation) and 9.8  M  H2O2 (Sigma-
Aldrich, Belgium). The digestion was performed at 110 °C 
for 18 h. The digest was then dried at 90 °C and the solid 
residue was re-dissolved in 5 mL of 8 M Optima™ grade 
HCl (Fisher Chemical, UK) and 0.001%  H2O2 to ensure 
that Cu is present in its Cu(II) oxidation state.
Cu was isolated by anion exchange chromatography 
using 1  mL of AG-MP-1 resin (Bio-Rad Laboratories, 
CA, USA) [12]. Two column passes ensure sufficient 
purity, while a quantitative recovery avoids potential 
on-column isotope fractionation effects from affecting 
the final Cu isotope ratio results. The purified Cu frac-
tions thus obtained were dried at 90  °C and the residue 
was re-dissolved in 1 mL of 14 M  HNO3. This was done 
twice to fully remove remaining chlorine. Finally, the Cu 
fractions were re-dissolved in 0.42 M  HNO3 for further 
elemental and isotopic analysis. Ultra-pure water (resis-
tivity > 18.2  MΩ cm) was used throughout this study 
(Milli-Q Element water purification system, Millipore, 
France). All sample manipulations were performed in a 
class-10 clean room.
Cu isotope ratio measurements were performed using 
a Neptune MC-ICP-MS instrument (Thermo Scientific, 
Germany), as described elsewhere [5]. Samples were 
measured in sample-standard bracketing (SSB) sequence 
using a solution of NIST SRM 976 Cu isotopic refer-
ence material (NIST, USA) as external standard. Cu 
concentrations in samples and standard were matched 
within ± 10%. The mass bias was corrected for using 
a combination of internal standardisation using Ga as 
internal standard, relying on the revised Russell’s law as 
described by Baxter et  al. [17], and external correction 
in an SSB approach. The Cu isotope ratio is expressed in 
delta notation as δ65Cu (‰), calculated as indicated in 
Eq. 1:
A Cu in-house standard (Inorganic Ventures, the Neth-
erlands) was measured every five samples to monitor the 
quality of the isotope ratio data. The Cu isotope ratio 
obtained for the in-house QC sample in this work was 
δ65Cu = 0.223 ± 0.009 (sd, n = 9), which corresponds well 
with the value obtained in our previous study [12].
Statistics
Statistical analysis was performed using Graphpad Prism 
(Graphpad Software Inc., San Diego, California) and 
SPSS Statistics 25 (IBM Corp., USA). Kruskall-Wallis and 
Dunn’s multiple comparisons test were used to compare 
groups and Receiver Operating Characteristic (ROC) 
analysis was performed. Spearman’s rank correlation 
coefficient was used to evaluate potential relationships 
between biochemical parameters and the Cu isotopic 
composition within the NAFLD population. P-values 
were two-sided and considered significant when lower 
than 0.05.
Results
In NAFLD patients, serum δ65Cu values were lower 
than in healthy controls (Fig.  1a), even at the level of 
simple steatosis (NAFL) (p ≤ 0.04), and remained sta-
ble during further disease progression (Fig.  1a). More 
specifically, average serum δ65Cu values were lower by 
0.57‰ ± 0.35‰ (sd), 0.71 ± 0.47‰ (sd), and 0.76 ± 0.51‰ 
(sd) in NAFL patients, NASH patients with F0–F2 fibro-
sis, and NASH patients with cirrhosis (F4), respectively. 
This suggests that the lower serum δ65Cu value is an early 
event in NAFLD and is thus already present before the 
onset of liver inflammation.
Importantly, ROC analysis shows an almost complete 
(AUC = 0.9896, p < 0.0001) diagnostic ability of serum 
δ65Cu values for NAFLD patients (Fig.  1b). In contrast, 
no further discrimination can be made between NAFL 
(1)
δ
65Cusample =
(
65Cu
/
63Cu
sample
65Cu
/
63Cu
NIST SRM976
− 1
)
× 1000
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and NASH patients (AUC = 0.6107, p = 0.36) or between 
NASH patients with F0–F2 fibrosis and with cirrhosis 
(F4) (AUC = 0.5500, p = 0.78). In addition, no relevant or 
significant correlations between clinical parameters and 
serum δ65Cu values within the NAFLD patient cohort 
were observed (max |ρ| = 0.22, Table 2).
Discussion
Lower serum δ65Cu values have been described in 
patients with end stage liver disease (cirrhosis), aris-
ing from several aetiologies, in cancer patients, and in 
patients with Wilson’s disease [4–8]. In addition, we have 
shown a whole-body enrichment of the light 63Cu isotope 
in an experimental model for secondary biliary fibrosis 
[18]. Our data align those previous results and further 
elaborate on serum δ65Cu values within different NAFLD 
stages. In agreement with previously published data of a 
bariatric cohort [11], serum δ65Cu values were lower in 
NAFLD patients. The variation of serum δ65Cu values 
in different stages of NAFLD had not been investigated 
thus far, and we show that, already at the level of sim-
ple steatosis, serum δ65Cu values are lower, and remain 
stable during further disease progression. We highlight 
lower serum δ65Cu values as diagnostic tool for NAFLD, 
irrespective of disease progression. Currently, patients 
are screened for steatosis by non-invasive imaging tech-
niques (such as ultrasound or the controlled attenuation 
parameter), which require patients to go to a hospital or 
center where this equipment is available [19]. In addi-
tion, the general practitioner can take blood samples for 
serum biomarker analysis (such as the fatty liver index or 
the SteatoTest). However, the diagnostic ability of these 
biomarkers for steatosis (AUROC ranging from 0.73–
0.86) can still be improved [19]. Our results show poten-
tial for serum δ65Cu to exceed the diagnostic ability of 
Fig. 1 Serum δ65Cu changes in non‑alcoholic fatty liver disease (NAFLD). a Serum δ65Cu values for different stages of NAFLD. Statistical analysis 
was performed by Kruskal–Wallis and Dunn’s multiple comparisons test. b Receiver Operating Characteristic (ROC) analysis of serum δ65Cu values. 
P‑values were two‑sided and considered significant when lower than 0.05. F0–F4 refers to the corresponding fibrosis stage. Healthy males: n = 12, 
healthy females: n = 10. Non‑alcoholic fatty liver (NAFL): n = 10. Non‑alcoholic steatohepatitis (NASH) F0–F2: n = 10. NASH F4: n = 4
Table 2 Spearman’s correlation analysis between  serum 
δ65Cu levels and  clinical parameters within  the  NAFLD 
patient cohort
NAFL non-alcoholic fatty liver, NASH: non-alcoholic steatohepatitis, BMI: body 
mass index, AST aspartate aminotransferase, ALT alanine aminotransferase, GGT 
γ-glutamyltransferase, Hb Haemoglobin, HbA1c haemoglobin A1c, LDL low-
density lipoprotein, HDL high-density lipoprotein, HOMA-IR Homeostasis Model 
Assessment Insulin Resistance, NAS NAFLD activity score
Spearman’s ρ p n
BMI (kg m−2) 0.03 0.89 24
Steatosis on liver biopsy − 0.22 0.34 21
Ballooning on liver biopsy − 0.20 0.37 21
Inflammation on liver biopsy − 0.09 0.71 21
NAS on liver biopsy − 0.19 0.42 21
Fibrosis on liver biopsy − 0.13 0.54 24
Presence of NASH (yes/no) − 0.19 0.38 24
AST (U  l−1) 0.25 0.23 24
ALT (U  l−1) 0.03 0.89 24
GGT (U  l−1) − 0.05 0.81 24
Bilirubin (mg dl−1) − 0.07 0.77 20
Glucose (mg dl−1) 0.24 0.30 20
HOMA‑IR 0.26 0.27 20
HbA1c (%) 0.09 0.70 23
Diabetes (yes/no) 0.19 0.39 24
Cholesterol (mg dl−1) 0.22 0.39 17
HDL (mg dl−1) − 0.10 0.71 17
LDL (mg dl−1) − 0.06 0.80 19
Triglycerides (mg dl−1) − 0.16 0.50 20
Ferritin (µg l−1) 0.24 0.33 19
Copper (µg dl−1) 0.10 0.69 18
Transferrin (mg dl−1) − 0.03 0.91 19
Iron (µg dl−1) − 0.03 0.92 19
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current serum biomarkers, and to diagnose patients with 
early NAFLD, a population that would benefit from early 
notification to prevent progression to NASH, for which 
no medical therapy is available so far.
Limitations
Although our patient population covers different stages 
of NAFLD, no obese patients without NAFLD were 
included. These patients could have revealed additional 
information about the initial stage and cause of the lower 
serum δ65Cu values. In addition, both genders were 
not equally represented in the different NAFLD stages. 
However, when we compare male and female healthy 
controls, the difference between average serum δ65Cu 
values was much smaller (0.12‰) than the observed dis-
ease effects (0.57–0.76‰) and not significant (Fig. 1a). A 
larger patient cohort could have also allowed to evaluate 
assay reproducibility and sensitivity. Nevertheless, serum 
δ65Cu values have previously been shown to be repro-
ducible in healthy controls [11–13], so that these results 
seem highly reliable.
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